Bipolar 1 Disorder

19 clinical trials · Condition

Record	Firm	Date
Efficacy of the Mobile Application for Prediction and Prevention of Mood Episode Recurrence Based on Machine Learning (NCT05400785)	Hucircadian	2022-05-27
CLOZAPINE Response in Biotype-1 (NCT04580134)	University of Texas Southwestern Medical Center	2022-03-01
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease (NCT04031469)	ProgenaBiome	2019-07-11
A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder (NCT03643159)	Otsuka Pharmaceutical Development & Commercialization, Inc.	2018-06-28
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder (NCT01981811)	Otsuka Pharmaceutical Development & Commercialization, Inc.	2014-03-01
Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia (NCT02050854)	Otsuka Pharmaceutical Development & Commercialization, Inc.	2013-12-01
Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder (NCT01674010)	OPKO Health, Inc.	2012-08-01
Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691) (NCT00764478)	Organon and Co	2012-04-06
Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384) (NCT01396291)	Forest Laboratories	2011-12-01
An Expanded Access Program (EAP) for OLZ/SAM in Pediatric Participants With Schizophrenia or Bipolar I Disorder (ALKS 3831-315) (NCT07744113)	Alkermes, Inc.

Track Bipolar 1 Disorder automatically

Every clearance here is in the API, with alerts when new ones post.